217 related articles for article (PubMed ID: 18657036)
21. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Jensen DM; Morgan TR; Marcellin P; Pockros PJ; Reddy KR; Hadziyannis SJ; Ferenci P; Ackrill AM; Willems B
Hepatology; 2006 May; 43(5):954-60. PubMed ID: 16628671
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
Antaki N; Hermes A; Hadad M; Ftayeh M; Antaki F; Abdo N; Kebbewar K
J Viral Hepat; 2008 May; 15(5):383-6. PubMed ID: 18086180
[TBL] [Abstract][Full Text] [Related]
23. Response of different HCV genotypes to interferon therapy in different age groups of chronic hepatitis-C patients.
Iqbal S; Khalil-Ur-Rahman ; Sheikh MA; Arshad M
J Ayub Med Coll Abbottabad; 2014; 26(3):310-5. PubMed ID: 25671935
[TBL] [Abstract][Full Text] [Related]
24. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.
Desmond CP; Roberts SK; Dudley F; Mitchell J; Day C; Nguyen S; Pianko S
J Viral Hepat; 2006 May; 13(5):311-5. PubMed ID: 16637861
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.
Chou R; Hartung D; Rahman B; Wasson N; Cottrell EB; Fu R
Ann Intern Med; 2013 Jan; 158(2):114-23. PubMed ID: 23437439
[TBL] [Abstract][Full Text] [Related]
26. Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial.
Shehab HM; Elbaz TM; Deraz DM
Liver Int; 2014 Feb; 34(2):259-65. PubMed ID: 23890273
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.
Huang CF; Yang JF; Dai CY; Huang JF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Infect Dis; 2010 Mar; 201(5):751-9. PubMed ID: 20102281
[TBL] [Abstract][Full Text] [Related]
29. [HCV Genotype Distribution in Southwest China and Its Influence on Patients' Response to Pegylated-interferon α-2a Plus Ribavirin Therapy].
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 46(4):573-7. PubMed ID: 26480661
[TBL] [Abstract][Full Text] [Related]
30. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
31. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.
Srivastava S; Bertagnolli M; Lewis JH
J Natl Med Assoc; 2005 Dec; 97(12):1703-7. PubMed ID: 16396063
[TBL] [Abstract][Full Text] [Related]
32. Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
Silva GF; Polônio RJ; Pardini MI; Corvino SM; Henriques RM; Peres MN; Silveira LV; Coelho KI
Braz J Infect Dis; 2007 Dec; 11(6):554-60. PubMed ID: 18327466
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
Sasadeusz JJ; Dore G; Kronborg I; Barton D; Yoshihara M; Weltman M
Addiction; 2011 May; 106(5):977-84. PubMed ID: 21205057
[TBL] [Abstract][Full Text] [Related]
34. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
Kohjima M; Yoshimoto T; Enjoji M; Fukushima N; Fukuizumi K; Nakamura T; Kurokawa M; Fujimori N; Sasaki Y; Shimonaka Y; Murata Y; Koyama S; Kawabe K; Haraguchi K; Sumida Y; Harada N; Kato M; Kotoh K; Nakamuta M
World J Gastroenterol; 2015 Mar; 21(11):3291-9. PubMed ID: 25805936
[TBL] [Abstract][Full Text] [Related]
35. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.
Rosina F; Tosti ME; Borghesio E; Masocco M; Mele A; Coppola C; Milella M; Borgia G; Andreone P; Koch M; Zignego AL; Romano M; Carrara M; Almasio PL; Azzola E; Nardone G; Benedetti A; Carosi G; Mazzotta F; Sagnelli E; Rizzetto M; ; ; ; ; ; ; ; ;
Dig Liver Dis; 2014 Sep; 46(9):826-32. PubMed ID: 24986781
[TBL] [Abstract][Full Text] [Related]
36. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.
Cooper C; Shafran S; Greenbloom S; Enns R; Farley J; Hilzenrat N; Williams K; Elkashab M; Abadir N; Neuman M
Can J Gastroenterol Hepatol; 2014 Jan; 28(1):35-40. PubMed ID: 24212915
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of pegylated interferon-alpha-2a plus ribavirin for patients aged at least 60 years with chronic hepatitis C.
Zheng YY; Fan XH; Wang LF; Tian D; Huo N; Lu HY; Wu CH; Xu XY; Wei L
Chin Med J (Engl); 2012 Jun; 125(11):1852-6. PubMed ID: 22884041
[TBL] [Abstract][Full Text] [Related]
38. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
Mohamed AA; Sabry NA; Abbassi MM; Ibrahim WA; Ali-Eldin ZA
Acta Gastroenterol Belg; 2013 Mar; 76(1):38-44. PubMed ID: 23650781
[TBL] [Abstract][Full Text] [Related]
39. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.
Wantuck JM; Ahmed A; Nguyen MH
Aliment Pharmacol Ther; 2014 Jan; 39(2):137-47. PubMed ID: 24251930
[TBL] [Abstract][Full Text] [Related]
40. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
Vogel M; Ahlenstiel G; Hintsche B; Fenske S; Trein A; Lutz T; Schürmann D; Stephan C; Khaykin P; Bickel M; Mayr C; Baumgarten A; Buggisch P; Klinker H; John C; Gölz J; Staszewski S; Rockstroh JK
Eur J Med Res; 2010 Mar; 15(3):102-11. PubMed ID: 20452894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
